NCT01234298
Withdrawn
Phase 3
A Phase 3 Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Low- and High-dose Range Groups of SPD489 as Adjunctive Treatment to Established Maintenance Doses of Antipsychotic Medications on Negative Symptoms in Clinically Stable Adults Who Have Persistent Predominant Negative Symptoms of Schizophrenia
ConditionsNegative Symptoms of Schizophrenia
Overview
- Phase
- Phase 3
- Intervention
- SPD489 Low-Dose
- Conditions
- Negative Symptoms of Schizophrenia
- Sponsor
- Shire
- Primary Endpoint
- Negative Symptom Assessment (NSA-16) total score
- Status
- Withdrawn
- Last Updated
- 4 years ago
Overview
Brief Summary
To assess the safety and efficacy of SPD489 low-dose and high-dose treatment groups to placebo when given as adjunctive therapy to antipsychotic medication in clinically stable adults with persistent predominant negative symptoms of schizophrenia.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Subject has diagnosis of schizophrenia for at least 2 years
- •Subject has persistent predominant negative symptoms
- •Subject has 2 or more persistent predominant negative symptoms (affective flattening, alogia, avolition apathy, and anhedonia-asociality) determined to have been present for at least 6 months
- •Subject is maintained on antipsychotic monotherapy or polytherapy with no more than 2 antipsychotic medications
- •Subject has been clinically stable and is in the non-acute phase of illness
Exclusion Criteria
- •Subject has clinically notable positive symptoms
- •Subject is considered to be treatment refractory
- •Subject has current history of substance abuse/dependance
- •Subject is considered a suicide risk or risk to harm others
Arms & Interventions
SPD489 Low-Dose
Intervention: SPD489 Low-Dose
SPD489 High-Dose
Intervention: SPD489 High-Dose
Placebo
Intervention: Placebo
Outcomes
Primary Outcomes
Negative Symptom Assessment (NSA-16) total score
Time Frame: up to 26 weeks
Secondary Outcomes
- Positive and Negative Syndrome Scale (PANSS)(up to 26 weeks)
Similar Trials
Completed
Phase 3
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating DisorderBinge Eating DisorderNCT01718483Shire383
Completed
Phase 3
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating DisorderBinge Eating DisorderNCT01718509Shire390
Withdrawn
Phase 3
Safety and Efficacy of SPD489 in Adolescent Subjects Aged 13-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)ADHDNCT01274221Shire
Terminated
Phase 3
Adjunctive SPD489 to Antipsychotic Medication in Clinically Stable Adults With Persistent Predominant Negative Symptoms of SchizophreniaSchizophreniaNCT01738698Shire4
Completed
Phase 3
Safety and Efficacy of SPD503 in Treating ADHD in Children and Adolescents Aged 6-17Attention Deficit Disorder With HyperactivityNCT00150618Shire324